In-depth AI-generated research on individual tickers. Grades, price targets, financials, and analyst context.
200 articles
LuxExperience is a selective Buy turnaround story: Mytheresa is compounding while the YNAP assets improve from drag to repair. The stock screens cheap at 0.37x revenue, but execution and cash burn still matter.
Amer Sports is compounding quickly as Arc’teryx and Salomon drive double-digit growth, margin expansion, and a higher-quality mix. The stock looks attractive on fundamentals, but valuation and execution risk keep it in buy-on-quality territory.
Agilysys is compounding revenue, expanding margins, and deepening its recurring mix across hospitality software. The stock looks high quality, but the valuation still leaves limited room for execution missteps.
Accenture is a high-quality compounder with record bookings, rising AI traction, and strong cash generation. The stock looks inexpensive relative to its durability, though growth remains mid-single-digit.
YPF is turning Vaca Muerta growth, lower lifting costs, and asset sales into a stronger cash flow story. Argentina risk remains, but the operating turnaround and leverage improvement make the setup attractive.
Dominion Energy combines regulated utility stability with unusual data-center-driven load growth and a major offshore wind buildout. The stock looks fairly valued, making execution the key driver rather than multiple expansion.
DexCom is back to a cleaner growth-and-margin profile, with double-digit revenue gains, expanding profitability, and a net cash balance supporting continued investment. The main debate is whether reimbursement expansion and international growth can offset intense CGM competition.
Intuit remains a high-quality compounder with accelerating growth across QuickBooks, TurboTax, and Credit Karma. Strong cash flow and expanding AI-driven monetization support a Buy rating despite a premium valuation.
ASML’s EUV monopoly, rising installed-base revenue, and AI-driven demand keep the business compounding. Valuation is rich, but the company’s profitability and outlook remain exceptional.
Versant Media Group is a newly independent media company trading at low multiples despite steady cash generation and growing digital platforms. The report argues the stock is a Buy, with legacy TV pressure offset by brand strength, licensing, and buybacks.
Manulife combines a cash-generative insurance base with faster-growth exposure in Asia and Global WAM. FY2025 results, a 10% dividend hike, and a new buyback plan support a disciplined Buy case.
Biogen is no longer just a declining MS story. Q1 2026 showed rising EPS, stronger free cash flow, and growing newer products, but full-year revenue still faces pressure.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator